XML 19 R8.htm IDEA: XBRL DOCUMENT
v3.23.1

Development-Stage Risks and Liquidity | 3 Months Ended
--- | ---
Mar. 31, 2023
Development-Stage Risks and Liquidity |
Development-Stage Risks and Liquidity |
(2) | Development-Stage Risks and Liquidity
The Company has incurred losses since inception and has an accumulated deficit of $182.9 million as of March 31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. Management believes that cash, cash equivalents and marketable securities of $139.0 million as of March 31, 2023 are sufficient to sustain planned operations through the end of 2024. The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

X
- References No definition available. + Details
Name: | carm_DevelopmentStageRisksAndLiquidityAbstract
Namespace Prefix: | carm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure on risks of development-stage and liquidity. + References No definition available. + Details
Name: | carm_DevelopmentStageRisksAndLiquidityTableTextBlock
Namespace Prefix: | carm_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration